ALK maintains China bet despite geopolitical unrest

Front lines between China and the Western world have gotten more pronounced recently. Despite this, Danish allergy company ALK is ramping up its activities in the communist-ruled country with double-digit investments this year. ”China is a huge opportunity for us,” CEO Carsten Hellmann tells MedWatch.

Carsten Hellmann, CEO of ALK | Photo: ALK / PR

In recent times, a string of Danish life science firms has been worried over rising geopolitical tensions between Western countries and China.

Doubts about the Communist Party of China’s strategy for foreign companies that operate in the country have had some players, like Novo Nordisk and medtech company Linak, take steps toward greater independence from the ruling party at the center of it all.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs